**EVICR.net Activities – Update**

EVICR.net – the European Vision Institute Clinical Research Network – is a network dedicated to perform multinational clinical research in ophthalmology with the highest standards of quality following the European and International Directives for Clinical Research according to harmonized standard operating procedures (SOPs). The network is a useful resource for the development and the coordination of investigator-initiated research (IIR) and for industry-driven clinical trials, contributing to strengthen the capacity of the European Union to explore and optimise diagnostic, prevention and treatment strategies in ophthalmology.

This European platform for multinational translational research in ophthalmology has presently 99 Clinical Site Members from 18 European countries as well as 7 industry partners, aiming to respond to the challenges of an increasing demand of better health-care assistance in ophthalmology.

The EVICR.net Coordinating Centre is located at AIBILI in Coimbra, Portugal, which is responsible for the management of the network and multinational clinical research.

**Aims and Objectives**

The main aims and objectives of EVICR.net are:

- to guarantee a high level of quality and excellence in the multinational clinical research performed according to International Conference on Harmonisation – Good Clinical Practice (ICH-GCP) Guidelines,
- to promote multinational IIR within the European Union,
- to serve as a resource for industry in performing clinical research in ophthalmology,
- to coordinate training activities for its members,
- to promote quality, transparency and optimal use of clinical research data, and
- to inform patients and citizens of the challenges and opportunities raised in ophthalmology clinical research.

**Organization**

The **General Assembly** consists of all EVICR.net members and is the supreme organ of the network.

The **Steering Committee** is responsible for the activities of the EVICR.net and acts as its decision-making body within the framework set by the General Assembly. The Steering Committee consists of up to 7 representatives: the Chairman, the Coordinator of each Expert Committee and the CEO of the Coordinating Centre.

The **Expert Committees** have a fundamental role in the scientific organization of EVICR.net and cover the following main areas of research: AMD and Retinal Dystrophies, Diabetic Retinopathy and Vascular Diseases, Glaucoma, Anterior Segment, and Reading Centres.

There are also two **Transversal Sections** that work together with the Expert Committees when applicable: Medical Devices and Rare Diseases.

The **Industry Advisory Board** advises the Steering Committee in all matters of strategic relevance, particularly pertaining collaborations with industry. The Industry Advisory Board is composed of individuals or representatives of companies who have given support to the activities of EVICR.net and at the moment is composed of Alcon, Allergan, Bayer, Novartis, Pfizer, Santen and Thèa.

The **Coordinating Centre**, AIBILI, is the contact point for the members and industry when performing ophthalmological clinical research in Europe. The Coordinating Centre is responsible for the coordination of IIR. Annually, the Coordinating Centre updates the EVICR.net Research Resources Directory where all members have their resources listed: staff, equipment and facilities as well as their scientific areas of clinical research and the 5 most relevant publications. All members have access to a restricted area on the website that is also kept updated by the Coordinating Centre. The Coordinating Centre is responsible for the certification of EVICR.net Clinical Site Members.
The 10th Annual Members Meeting took place in Rome, Italy, on November 26–27, 2015. The meeting was attended by about 100 participants from member centres (table 1; fig. 1), contract research organizations (CROs) and Industry Advisory Board members. The 11th EVICR.net Annual Meeting will take place in Antwerp, Belgium, on November 9–10, 2016.

**Investigator-Initiated Research and Registries**

The EVICR.net Coordinating Centre is responsible for the coordination and management of IIR in ophthalmology across Europe through the network. EVICR.net members have the opportunity to submit abstracts for IIR to the Coordinating Centre in order to be evaluated by a specific Expert Committee. If approved, they will have access to support in developing and implementing the IIR. Also, EVICR.net members have the opportunity to participate in IIR developed by the network or in industry-sponsored clinical trials.

EVICR.net IIR has been growing in the last years, giving the opportunity to investigators to perform multinational clinical research of high quality (ICH-GCP compliant), assuming that the rights, safety and wellbeing of the trial subjects are protected and that the clinical data are credible. EVICR.net has contributed to the improvement of diagnostic, prevention and treatment strategies in ophthalmology. EVICR.net has presently 8 ongoing multinational clinical research studies, of which 3 are European Union funded, 4 obtained industry grants and 1 is an industry registry (tables 2, 3; fig. 2).

### Table 1. Number of members per country

<table>
<thead>
<tr>
<th>Country</th>
<th>No.</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Belgium</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Denmark</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Finland</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>France</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>Greece</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Ireland</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Israel</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Italy</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Poland</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Portugal</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>Slovakia</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Slovenia</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Spain</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>Switzerland</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>The Netherlands</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>United Kingdom</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>99</td>
<td></td>
</tr>
</tbody>
</table>

### Table 2. Multinational clinical research studies (2010–2016)

<table>
<thead>
<tr>
<th>Year</th>
<th>IIR</th>
<th>EU funding</th>
<th>Industry grant</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>2</td>
<td>–</td>
<td>–</td>
<td>2</td>
</tr>
<tr>
<td>2011</td>
<td>2</td>
<td>1</td>
<td>–</td>
<td>3</td>
</tr>
<tr>
<td>2012</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>2013</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>11</td>
</tr>
<tr>
<td>2014</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>12</td>
</tr>
<tr>
<td>2015</td>
<td>–</td>
<td>3</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>2016</td>
<td>–</td>
<td>3</td>
<td>4</td>
<td>1</td>
</tr>
</tbody>
</table>

**Annual Members Meeting**

The 10th Annual Members Meeting took place in Rome, Italy, on November 26–27, 2015. The meeting was attended by about 100 participants from member centres (table 1; fig. 1), contract research organizations (CROs) and Industry Advisory Board members. The 11th EVICR.net Annual Meeting will take place in Antwerp, Belgium, on November 9–10, 2016.

### Fig. 1. Number of members per country (a total of 99 sites).

### Fig. 2. Number of multinational clinical research studies.
### AMD and Retinal Dystrophies

**Clinical Trials**
2. ATLANTIC – A randomized, double-masked, sham-controlled phase 4 study of the efficacy, safety and tolerability of intravitreal aflibercept monotherapy compared to aflibercept with adjunctive photodynamic therapy in patients with polypoidal choroidal vasculopathy. IIR grant from Bayer. EudraCT No. 2015-001368-20; ClinicalTrials.gov No. NCT02495181.

### Diabetic Retinopathy and Vascular Diseases

**Clinical Trials**
1. EUROCONDOR – Neurodegeneration as an early event in the pathogenesis of diabetic retinopathy: a multicentric, prospective, phase II/III, double-blind randomized controlled trial to assess the efficacy of neuroprotective drugs administered topically to prevent or arrest diabetic retinopathy. EU-funded project. EudraCT No. 2012-001200-38; ClinicalTrials.gov No. NCT01726075.
2. PROTEUS – Prospective, randomized, multicenter, open-label, phase II/III study to assess the efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus PRP in monotherapy in the treatment of patients with high-risk proliferative diabetic retinopathy. IIR grant from Novartis. EudraCT No. 2013-003640-23; ClinicalTrials.gov No. NCT01941329.

**Registry**

### Glaucoma

**Clinical Trials**
1. STRONG – European Consortium for the Study of a Topical Treatment of Neovascular Glaucoma. EU-funded project.

### Table 3. Multinational clinical research studies per ophthalmology subspecialty (May 2016)

<table>
<thead>
<tr>
<th>Ongoing clinical research</th>
<th>Area of subspecialty</th>
<th>AMD and Retinal Dystrophies</th>
<th>Diabetic Retinopathy and Vascular Diseases</th>
<th>Glaucoma</th>
<th>Anterior Segment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical trials (IIR)</td>
<td>EUR-USHA&lt;br&gt;ATLANTIC²&lt;br&gt;PROTEUS²&lt;br&gt;ARTES²</td>
<td>STRONG²</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Registry (industry)</td>
<td>IRISS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>2</td>
<td>4</td>
<td>2</td>
<td>0</td>
</tr>
</tbody>
</table>

² EU-funded. ¹ Industry grant.

### Publications

**AMD and Retinal Dystrophies**
  - EVER 2014 (poster)

**Diabetic Retinopathy and Vascular Diseases**
  - ARVO 2014 Congress (poster)
  - ARVO 2015 Congress (poster)
  - Ophthalmic Res 2015;54:112–117
  - Ophthalmic Res 2015;54:118–123
- ECR-RET-2011-03 – EUROCONDOR – Neurodegeneration as an early event in the pathogenesis of diabetic retinopathy: a multicentric, prospective, phase II/III, double-blind randomized controlled trial to assess the efficacy of neuroprotective drugs administered topically to prevent or arrest diabetic retinopathy. EU-funded project. EudraCT No. 2012-001200-38; ClinicalTrials.gov No. NCT01726075.
  - ARVO 2014 Congress (poster)
  - ARVO 2015 Congress (poster)
  - Invest Ophthalmol Vis Sci 2015;56:1802
  - ARVO 2016 Congress (poster)
  - EASDec 2016 (5 presentations)
Standard Operating Procedures

EVICR.net has developed a quality system for its members compliant with ICH-GCP Guidelines. It provides 9 Organizational SOPs for free to its members. All EVICR.net Clinical Sites Members agree to adopt or adapt these SOPs in their centres, which will be checked before they are certified as Sites of Excellence. An independent evaluation visit may occur before this certification.

The implementation of these 9 Organizational SOPs will permit the Clinical Sites to have a common standard way of working and in compliance with ICH-GCP Guidelines when performing clinical research.

EVICR.net has also developed 31 Technical SOPs for performing specific ophthalmic examinations or evaluations that can be used within the Network for Clinical Trials. These SOPs are also made available to our members.

In parallel, EVICR.net has developed 22 Organizational SOPs for the Reading Centres so they can work as a network of Reading Centres and be able to have the capacity to respond to the industry needs for grading ophthalmological images in a standardised way with the most novel equipment.

Clinical Sites Certification

At the moment, we have 57 Clinical Sites certified, of which 46 are re-certified (more than 2-year certificate).

Educational Programme

An Educational Programme is being implemented within the EVICR.net activities. On April 10, 2016, an OCT Course took place in Milan, Italy, in association with the 2nd San Raffaele OCT Forum. Another OCT Course is now planned to take place in association with the 11th Annual Members Meeting in Antwerp, Belgium, on November 9–10, 2016. A programme with CME credits is now being organized on Clinical Research Methodologies as they are applied to ophthalmology and investigator-initiated clinical research trials.

Collaboration with ECRIN – European Clinical Research Infrastructure Network

EVICR.net, as a disease-oriented network in ophthalmology for clinical research, is an affiliate partner of ECRIN-ERIC, the European Clinical Research Infrastructure Network.

Since ECRIN-ERIC is a network for investigator-initiated multicentre clinical research in Europe in any scientific area, EVICR.net serves as a resource to ECRIN-ERIC in the area of vision and ophthalmology clinical research, particularly providing scientific and medical expertise, access to patients and clinical research capacity in ophthalmology through its members in an organized manner and compliant with ICH-GCP Guidelines and the European Regulation for Clinical Research.

Alliances and Partnerships

EVICR.net has established preferred alliances with two CROs, AppleTree (Switzerland) and Eurotrials (Portugal), for the EVICR.net Clinical Site certification process to perform an independent evaluation visit of the Clinical Sites. Collaborations are being established with other CROs in order to move forward multinational clinical research in ophthalmology.

EVICR.net – European Network of Clinical Research in Ophthalmology

Chairman
Jose Sahel, MD, PhD

Steering Committee
Jose Sahel, MD, PhD – AMD and Retinal Dystrophies Expert Committee Coordinator
José Cunha-Vaz, MD, PhD – Diabetic Retinopathy and Vascular Diseases Expert Committee Coordinator
Francesca Cordeiro, MD, PhD – Glaucoma Expert Committee Coordinator
Marie-José Tassignon, MD, PhD – Anterior Segment Expert Committee Coordinator
Tunde Peto, MD, PhD, FHCO, FHCD – Reading Centres Expert Committee Coordinator
Jorge Alió, MD, PhD – Medical Devices Transversal Section Coordinator
Birgit Lorenz, MD, PhD – Rare Diseases Transversal Section Coordinator
Cecília Martinho, BSc – CEO, Coordinating Centre (AIBILI)

Contacts
EVICR.net
AIBILI, Azinhaga de Santa Comba, Celas
PT–3000-548 Coimbra (Portugal)
Tel. +351 239 480 101/15, Fax +351 239 480 117
E-Mail evicrnet @ aibilipi.pt, Website www.evicr.net
### List of EVICR.net Members (per Country)

#### Austria (1)
- **CS No. 19:** Medical University of Vienna, Department of Ophthalmology, Vienna

#### Belgium (3)
- **CS No. 8:** Ghent University Hospital, Department of Ophthalmology, Ghent
- **CS No. 12:** Antwerp University Hospital, Department of Ophthalmology, Antwerp
- **CS No. 18:** University Hospitals Leuven, Department of Ophthalmology, Leuven

#### Denmark (2)
- **CS No. 30:** Rigshospitalet – Glostrup, Department of Ophthalmology, Copenhagen University, Glostrup
- **CS No. 73:** Odense University Hospital, Department of Ophthalmology, Odense

#### Finland (1)
- **CS No. 91:** Department of Ophthalmology, Kuopio University Hospital, Kuopio

#### France (12)
- **CS No. 3:** Centre Hospitalier Creteil, University Eye Clinic, Paris
- **CS No. 6:** Centre National d’Ophtalmologie des Quinze-Vingts, Centre d’Investigation Clinique, Paris
- **CS No. 13:** CHU Gabriel Montpied, Unité de Recherche Clinique, Service d’Ophtalmologie, Clermont-Ferrand
- **CS No. 14:** Hôpital Lariboisière, Department of Ophthalmology, Paris
- **CS No. 42:** University Hospital, CHU Dijon, Department of Ophthalmology, Dijon
- **CS No. 48:** CLAIROP – Centre Loco-Regional de l’AP-HP Necker pour l’Innovation et la Recherche en Ophtalmologie Pédriatrique, Paris
- **CS No. 61:** CHU Pellegrin, Service Optométrie, Bordeaux
- **CS No. 85:** Centre Hospitalier Universitaire Amiens-Picardie, Service d’Ophtalmologie, Amiens
- **CS No. 92:** Clinical Trial Unit, Department of Ophthalmology, CHU Nord, Aix Marseille University, Marseille
- **CS No. 93:** Department of Ophthalmology, Centre Hospitalier Henri Dufour, Avignon
- **CS No. 97:** Centre Optométrie de l’Oden, Paris
- **CS No. 99:** Department of Ophthalmology, Croix Rousse University Hospital, Lyon

#### Germany (15)
- **CS No. 2:** University Medical Center, Johannes Gutenberg University, Department of Ophthalmology, Mainz
- **CS No. 5:** Faculty of Medicine Mannheim of the Ruprecht-Karls-University Heidelberg, Department of Ophthalmology, Mannheim
- **CS No. 9:** University Hospital Tübingen (UKT), STZ Biomed & STZ EyeTrial, Center for Ophthalmology, Tübingen
- **CS No. 11:** University Eye Hospital Munich, Munich
- **CS No. 15:** University of Bonn, Department of Ophthalmology, Bonn
- **CS No. 21:** University Medical Center Hamburg-Eppendorf, Department of Ophthalmology, Hamburg
- **CS No. 24:** University of Freiburg, Department of Ophthalmology, Freiburg
- **CS No. 27:** University Eye Hospital, Leipzig
- **CS No. 43:** RWTH Aachen University, Department of Ophthalmology, Aachen

#### Greece (1)
- **CS No. 71:** Laboratory of Research and Clinical Applications in Ophthalmology, Aristotle University of Thessaloniki, 1st Department of Ophthalmology, AHEPA University Hospital, Thessaloniki

#### Ireland (1)
- **CS No. 31:** Mater Vision Institute (MVI), Dublin

#### Israel (3)
- **CS No. 60:** Tel Aviv Sourasky Medical Center, Department of Ophthalmology, Tel Aviv
- **CS No. 88:** Kaplan Medical Center, Ophthalmology Department, Rehovot
- **CS No. 100:** Meir Medical Center, Kfar-Saba

#### Italy (10)
- **CS No. 16:** University of Milan, Centre for Clinical Trials at San Paolo Hospital, Milan
- **CS No. 20:** G.B. Bietti Foundation – IRCCS, Rome
- **CS No. 34:** Luigi Sacco Hospital, University of Milan, Department of Ophthalmology, Milan
- **CS No. 36:** Catholic University, Institute of Ophthalmology, Rome
- **CS No. 37:** Dipartimento di Scienze Biomediche, Biotecnologiche e Traslazionali S.Bi.Bi.T., Parma
- **CS No. 39:** University of Padova, Department of Ophthalmology, Center for Clinical Trials, Padova
- **CS No. 50:** University of Udine, Department of Ophthalmology, Udine
- **CS No. 63:** University G. d’Annunzio of Chieti-Pescara, Excellence Eye Research Centre, Chieti
- **CS No. 64:** Ophthalmic Research Unit, Department of Basic Medical Sciences, Neuroscience and Sense Organs, Bari
- **CS No. 67:** University Vita Salute – Scientific Institute of San Raffaele, Department of Ophthalmology, Milan

#### Poland (1)
- **CS No. 33:** Poznan University of Medical Sciences, Department of Ophthalmology, Poznan

#### Portugal (13)
- **CS No. 1:** AIBILL – Association for Innovation and Biomedical Research on Light and Image, Coimbra
- **CS No. 28:** Instituto de Oftalmologia Dr. Gama Pinto, Lisbon
- **CS No. 32:** Oporto Medical School – Hospital S. João, Department of Ophthalmology, Oporto
- **CS No. 62:** Centro Hospitalar de Lisboa Central, Centro de Investigação, Serviço de Oftalmologia, Lisbon
- **CS No. 70:** University Hospital of Coimbra, Ophthalmology Department, Coimbra
CS No. 80: Instituto de Retina e Diabetes Ocular de Lisboa (IRL), Lisbon
CS No. 82: Espaço Médico de Coimbra, Coimbra
CS No. 90: Serviço de Oftalmologia, Hospital de Vila Franca de Xira, Vila Franca de Xira
CS No. 101: ALM-Óftalmolaser, Lisbon
CS No. 102: Instituto Português de Microcirurgia Ocular (IMO), Lisbon
CS No. 103: Serviço de Oftalmologia, Hospital de Braga, Braga
CS No. 104: Centro de Investigação, Serviço de Oftalmologia, Centro Hospitalar de Leiria E.P.E., Leiria
CS No. 107: Serviço Oftalmologia, Centro Hospitalar Porto-HSA, Oporto

Slovakia (1)
CS No. 87: Department of Ophthalmology, University Hospital, Comenius University, Bratislava

Slovenia (1)
CS No. 23: University Medical Centre of Ljubljana, University Eye Hospital, Ljubljana

Spain (15)
CS No. 7: Vissum Corporación Oftalmológica Alicante, Alicante
CS No. 26: Centro de Oftalmología Barraquer, Barcelona
CS No. 38: Institut Català de Retina (ICR), Clinical Trial Unit, Barcelona
CS No. 41: Centro Médico Teknon, Institut de la Màcula i de la Retina, Barcelona
CS No. 51: Fundación para la Investigacion Biomedica y Sanitaria (FISABIO) – Oftalmologia Médica, Valencia
CS No. 52: University Hospital Josep Trueta de Girona, Department of Ophthalmology, Girona
CS No. 74: Hospital Vall d’Hebron, Department of Ophthalmology, Barcelona
CS No. 75: Vallès Oftalmologia Research, Barcelona
CS No. 78: Instituto Oftalmológico Fernández-Vega, Oviedo
CS No. 89: Hospital Universitat de Las Palmas de Gran Canaria
CS No. 95: Instituto de Microcirugía Ocular, Barcelona
CS No. 96: Ophthalmology Department, Hospital de La Paz, Madrid
CS No. 98: Servicio Oftalmología, Hospital Universitario y Politécnico de la Fe, Valencia
CS No. 105: Unidad Clínica de Retina – Servicio de Oftalmología, Complejo Hospitalario Universitario de Albacete, Albacete
CS No. 109: Fundación Jiménez Díaz University Hospital, Department of Ophthalmology, Madrid

Switzerland (5)
CS No. 22: Inselspital, University of Bern, Department of Ophthalmology, Bern
CS No. 49: Jules Gonin Eye Hospital, Fondation Asile des Aveugles, Lausanne
CS No. 85: Clinical Research Centre, Mémorial A. de Rothschild, Geneva
CS No. 108: MIO SA, Lausanne
CS No. 110: University Hospital Basel, University Eye Clinic, Basel

The Netherlands (5)
CS No. 17: Department of Ophthalmology, Radboud University Medical Centre, Nijmegen
CS No. 25: Academic Medical Center, Department of Ophthalmology, Amsterdam
CS No. 40: Rotterdam Eye Hospital, Rotterdam
CS No. 76: University Eye Clinic, Maastricht
CS No. 106: Department of Ophthalmology, Leiden University Medical Center, Leiden

United Kingdom (9)
CS No. 10: NIHR Moorfields Clinical Research Facility, Moorfields Eye Hospital, NHS Foundation Trust, London
CS No. 35: The Queen’s University and Royal Group of Hospital Trust, Ophthalmology and Vision Science, Belfast
CS No. 53: Gloucestershire Hospital NHS Foundation Trust, Clinical Trials Unit, Department of Ophthalmology, Cheltenham
CS No. 58: Royal Liverpool University Hospital, Clinical Eye Research Centre, St. Paul’s Eye Unit, Liverpool
CS No. 66: Frimley Park Hospital Foundation Trust, Ophthalmology Clinical Trials Unit, Frimley
CS No. 68: Heart of England NHS Trust, Ophthalmic Research Unit, Birmingham
CS No. 69: King’s Health Partners, Laser and Retinal Research Unit, London
CS No. 81: Royal Surrey County Hospital, NHS Foundation Trust, Ophthalmic Research Unit, Guildford
CS No. 84: ICORG – Imperial College Ophthalmologic Research Group, London

Prepared by C. Martinho, D. Fernandes and M.V. Nascimento.